Collectively, this study identifies that LYRM2 as a novel oncogenic protein in HCC and elucidates its contribution to HCC progression through enhancing HIF‐1α‐dependent glucose metabolic reprogramming. The gene discussed is LYRM2; the disease is hepatocellular carcinoma.